Biomedical subjects

Christopher Rizzo

Publications and source records attributed to Christopher Rizzo.

6 recordsLinked to original sources

PubMed2006

Maximizing office-based immunization.

Vaccines are a great public health achievement only if we can deliver those vaccines to individual patients. It is impressive that gradually increasing immunization rates are so consistent in spite of a new birth cohort every year, complexity of the schedule, shortages, changes in reimbursement policies, and vaccine news stories. Pediatricians have always embraced their public health role, especially as immunization providers. By helping practices improve their immunization delivery system, rates can be raised throughout a community by first maximizing office-based immunization.

Child↗

PubMed2006

Improving immunization rates in practice settings.

Many pediatricians do not know the immunization rate of patients in their practice. Evidence-based standards of practice have been established, leading to improved rates. Quality improvement efforts aimed at immunization are effective and may lead to improvement in other preventive health services. By providing more vaccines in the medical home, communities can decrease the need for higher cost case management and outreach services targeting patients with delayed immunizations.

Child↗

PubMed2006

Linking practices with community programs to improve immunization rates.

Pediatricians should be knowledgeable about programs available in their community and support efforts to collaborate with other providers, public health departments and immunization coalitions in their community. Through immunization coalitions and widespread use of an immunization registry, together with participating private providers, case management and home visitation programs can improve immunization rates among the highest risk children.

Child↗

PubMed2005

Utility of lab-on-a-chip technology for high-throughput nucleic acid and protein analysis.

On-chip electrophoresis can provide size separations of nucleic acids and proteins similar to more traditional slab gel electrophoresis. Lab-on-a-chip (LoaC) systems utilize on-chip electrophoresis in conjunction with sizing calibration, sensitive detection schemes, and sophisticated data analysis to achieve rapid analysis times (<120 s). This work describes the utility of LoaC systems to enable and augment systems biology investigations. RNA quality, as assessed by an RNA integrity number score, is compared to existing quality control (QC) measurements. High-throughput DNA analysis of multiplex PCR samples is used to stratify gene sets for disease discovery. Finally, the applicability of a high-throughput LoaC system for assessing protein purification is demonstrated. The improvements in workflow processes, speed of analysis, data accuracy and reproducibility, and automated data analysis are illustrated.

DNA↗

PubMed2002

Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.

NMR spectroscopy was used to characterize the hepatitis C virus (HCV) NS3 protease in a complex with the 24 residue peptide cofactor from NS4A and a boronic acid inhibitor, Ac-Asp-Glu-Val-Val-Pro-boroAlg-OH. Secondary-structure information, NOE constraints between protease and cofactor, and hydrogen-deuterium exchange rates revealed that the cofactor was an integral strand in the N-terminal beta-sheet of the complex as observed in X-ray crystal structures. Based upon chemical-shift perturbations, inhibitor-protein NOEs, and the protonation state of the catalytic histidine, the boronic acid inhibitor was bound in the substrate binding site as a transition state mimic. In the absence of cofactor, the inhibitor had a lower affinity for the protease. Although the inhibitor binds in the same location, differences were observed at the catalytic site of the protease.

Binding Sites↗

PubMed2002

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

Induction of cytochrome P450 3A4 (CYP3A4) is determined typically by employing primary culture of human hepatocytes and measuring CYP3A4 mRNA, protein and microsomal activity. Recently a pregnane X receptor (PXR) reporter gene assay was established to screen CYP3A4 inducers. To evaluate results from the PXR reporter gene assay with those from the aforementioned conventional assays, 14 drugs were evaluated for their ability to induce CYP3A4 and activate PXR. Sandwiched primary cultures of human hepatocytes from six donors were used and CYP3A4 activity was assessed by measuring microsomal testosterone 6beta-hydroxylase activity. Hepatic CYP3A4 mRNA and protein levels were also analyzed using branched DNA technology/Northern blotting and Western blotting, respectively. In general, PXR activation correlated with the induction potential observed in human hepatocyte cultures. Clotrimazole, phenobarbital, rifampin, and sulfinpyrazone highly activated PXR and increased CYP3A4 activity; carbamazepine, dexamethasone, dexamethasone-t-butylacetate, phenytoin, sulfadimidine, and taxol weakly activated PXR and induced CYP3A4 activity, and methotrexate and probenecid showed no marked activation in either system. Ritonavir and troleandomycin showed marked PXR activation but no increase (in the case of troleandomycin) or a significant decrease (in the case of ritonavir) in microsomal CYP3A4 activity. It is concluded that the PXR reporter gene assay is a reliable and complementary method to assess the CYP3A4 induction potential of drugs and other xenobiotics.

Adult↗